Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SGN-PDL1V in advanced solid tumors
NL-OMON51357Phase 1Not yet recruiting
- Sponsor
- Seagen Inc.
- Start
- Jun 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SGN-PDL1V in non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), triple-negative breast cancer (TNBC) and 3 more (3 arms), sponsored by Seagen Inc. Primary endpoints: Adverse events and laboratory abnormalities, Dose-limiting toxicities and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
SGN-PDL1V
03
Conditions
non-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)Esophageal Squamous Cell Carcinoma (ESCC)ovarian cancer
Beyond the preview
Go deeper on NL-OMON51357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51357.